Results 41 to 50 of about 537,211 (318)
OncoImmunology, 2018 Memory CD8+ T cell responses have the potential to mediate long-lasting protection against cancers. Resident memory CD8+ T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens.
Felipe Gálvez-Cancino +13 more
doaj +1 more source
Immunotherapy through the Lens of Non-Small Cell Lung Cancer [PDF]
, 2023 Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, the discovery of CTLA-4 followed by PD-1 in the early 2000s led to the practice-changing clinical development of immune checkpoint inhibitors (ICI ...
Saoirse Flanagan +5 more
core +1 more source
Journal of the Royal College of Physicians of London, 1999 A forward looking conference took place at the Royal College of Physicians in June 1998. The audience, which included many scientific and clinical immunologists from both the university and pharmaceutical sector, participated knowledgeably and critically in the discussions on possible future treatments for immunologically caused diseases and on the ...
openaire +2 more sources
Aptamers in Immunotherapy [PDF]
Human Gene Therapy, 2008 Numerous nucleic acid ligands, also termed decoys or aptamer, have been developed during the past 20 years that can bind to and inhibit the activity of many proteins. The concept that nucleic acid ligands could modulate the activity of proteins emerged from basic science studies of viruses and early work in the field of gene therapy.
Claudia M, Dollins +2 more
openaire +2 more sources
NEW ROLES FOR FC RECEPTORS IN NEURODEGENERATION-THE IMPACT ON IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE [PDF]
, 2014 There are an estimated 18 million Alzheimer’s disease (AD) sufferers worldwide and with no disease modifying treatment currently available, development of new therapies represents an enormous unmet clinical need.
Teeling, Jessica L. +5 more
core +1 more source
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma [PDF]
, 2020 Immunotherapy targeting T-cell inhibitory receptors, namely programmed cell death-1 (PD-1) and/or cytotoxic T-lymphocyte associated protein-4 (CTLA-4), leads to durable responses in a proportion of patients with advanced metastatic melanoma.
Helen Rizos +14 more
core +1 more source
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Genome Medicine, 2018 For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout +2 more
doaj +1 more source
Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity
Frontiers in Oncology, 2021 Although abscopal tumor regression remains a rare phenomenon, interest in exploiting how radiation stimulates the immune system to induce systemic abscopal response is increasing.
Jin-Zhi Lai +7 more
doaj +1 more source
International Journal of Clinical Practice, 1989 A new era of immunotherapy is arriving in medical therapeutics. Both immunosupresion and immunomodulation have advantages which the clinician must learn. In this review, the author describe several immunomodulators which include cytokines, interleukins, interferons, tumor necrosis factor, granulocyte colony-stimulating factor, erythropoietin, and ...
openaire +4 more sources
Immunotherapy of lymphomas [PDF]
Journal of Clinical Investigation, 2020 Lymphoid malignancies typically promote an infiltrate of immune cells at sites involved by the disease. While some of the immune cells present in lymphoma have effector function, the immune system is unable to eradicate the malignant clone. Therapies that optimize immune function therefore have the potential to improve the outcome of lymphoma patients.
Stephen M, Ansell, Yi, Lin
openaire +2 more sources